Treatment and outcome among patients with laryngeal squamous cell carcinoma in Stockholm-A population-based study.

Autor: Blomkvist R; Division of ENT Diseases, Department of Clinical Science Intervention and Technology, Karolinska Institutet Stockholm Sweden.; Department of Otorhinolaryngology Karolinska University Hospital Stockholm Sweden., Marklund L; Division of ENT Diseases, Department of Clinical Science Intervention and Technology, Karolinska Institutet Stockholm Sweden.; Medical Unit, Head Neck, Lung and Skin Cancer Karolinska University Hospital Stockholm Sweden., Hammarstedt-Nordenvall L; Division of ENT Diseases, Department of Clinical Science Intervention and Technology, Karolinska Institutet Stockholm Sweden.; Medical Unit, Head Neck, Lung and Skin Cancer Karolinska University Hospital Stockholm Sweden., Gottlieb-Vedi E; Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery Karolinska Institutet and Karolinska University Hospital Stockholm Sweden., Mäkitie A; Division of ENT Diseases, Department of Clinical Science Intervention and Technology, Karolinska Institutet Stockholm Sweden.; Department of Otorhinolaryngology - Head and Neck Surgery University of Helsinki and Helsinki University Hospital Helsinki Finland., Palmgren B; Division of ENT Diseases, Department of Clinical Science Intervention and Technology, Karolinska Institutet Stockholm Sweden.; Medical Unit, Head Neck, Lung and Skin Cancer Karolinska University Hospital Stockholm Sweden.
Jazyk: angličtina
Zdroj: Laryngoscope investigative otolaryngology [Laryngoscope Investig Otolaryngol] 2023 Mar 06; Vol. 8 (2), pp. 441-449. Date of Electronic Publication: 2023 Mar 06 (Print Publication: 2023).
DOI: 10.1002/lio2.1034
Abstrakt: Objective: Survival of patients with advanced laryngeal squamous cell carcinoma (LSCC) remains poor and management protocols warrant further development. We thus investigated treatment and outcome-related factors for LSCC in Stockholm, Sweden.
Methods: In a retrospective setting, 520 patients with LSCC diagnosed during 2000-2014, were included. Data on stage, treatment, and outcome were correlated with recurrence-free and overall survival (RFS and OS, respectively).
Results: Five-year OS for all patients was 65%. Five-year RFS for T1a, T1b, T2, T3, and T4 glottic LSCC was 90%, 91%, 77%, 47%, and 80%, respectively. The corresponding figures for T1, T2, T3, and T4 supraglottic LSCC were 64%, 66%, 64%, and 86%.
Conclusion: Patients with a T3 glottic LSCC had unexpectedly poor survival, especially when compared with patients with a T4 tumor. Patients with T4 disease were primarily treated with laryngectomy and postoperative radiotherapy (RT)/chemoradiotherapy (CRT), while most patients with T3 LSCC were treated with RT/CRT.
Competing Interests: Eivind Gottlieb‐Vedi declares employment at Sanofi.
(© 2023 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje